Back to search results

Xaluritamig for Relapsed or Refractory Ewing Sarcoma

This study is testing a drug called xaluritamig in adults, teenagers, and children with Ewing Sarcoma (EWS) that has come back (relapsed) or hasn't responded to other treatments (refractory). The main goals are to find the right dose of xaluritamig and to understand its safety and any side effects. To join, you must have Ewing Sarcoma confirmed by a biopsy and show specific genetic changes (an EWSR1 translocation). The study is looking for about 50 participants. The current status of the study is unclear.

Study design
This study is an interventional trial, meaning participants will receive a specific treatment. It plans to enroll about 50 participants.
What's involved
Participants will receive xaluritamig through a short-term intravenous (IV) infusion. The study will track side effects for up to approximately 2.5 years.
Compensation
Not stated in the trial record.
Follow-up
The study will track treatment-emergent adverse events (side effects) for up to approximately 2.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07297979

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Recruiting
PHASE1Ages 2+InterventionalBasic science
Amgen
~50 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:Xaluritamig

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)
Measured over Up to 42 days
+1 more outcome measured

Conditions

Ewing Sarcoma

Explore related trials

Ewing SarcomaEWSR1 Gene

Where it's being run

9 sites across 8 states
California2
Massachusetts1
New York1
Pennsylvania1
Texas1
New South Wales1
Victoria1
Western Australia1

Study leadership

  • MD · STUDY_DIRECTOR · Amgen

Who to contact

Amgen Call Center
[email protected]
866-572-6436
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

the participant has not received short-acting growth factor support within 7 days before screening assessment, and
the participant has not received long-acting growth factor support within 14 days before screening assessment.
the participant has not received a platelet transfusion within 7 days before screening assessment, and
the participant has not received a platelet stimulating agent within 14 days before screening assessment.

What this trial measures

  • Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)Up to 42 days
  • Number of Participants with Treatment-emergent Adverse EventsUp to approximately 2.5 years

    This includes treatment-emergent, treatment-related, serious, and fatal adverse events. Any changes in safety assessments (vital signs and clinical laboratory tests) will be recorded as adverse events.